Skip Navigation

European Journal of Heart Failure 2005 7(7):1095-1098; doi:10.1016/j.ejheart.2005.01.015
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Izgi, C.
Right arrow Articles by Ozkan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izgi, C.
Right arrow Articles by Ozkan, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society of Cardiology

Serum anti-p53 antibodies do not occur in patients with heart failure due to idiopathic dilated and ischemic cardiomyopathies

Cemil Izgi, Cihan Cevik, Nihal Ozdemir, Cihangir Kaymaz and Mehmet Ozkan*

Kosuyolu Heart & Research Hospital Istanbul, Turkey

* Corresponding author. E-mail address: memoozkan{at}superonline.com


  Abstract

Background: P53 is a key protein which controls cell cycle arrest and apoptosis in response to DNA damage. Auto-antibodies against p53 have been detected in some cancer patients and also in patients with autoimmune diseases. In these patients, the main cause of anti-p53 antibody occurrence was considered to be increased intracellular p53 protein in cancer cells and autoreactive lymphocytes, respectively. Intracellular p53 also increases with cardiomyocyte apoptosis during heart failure and autoreactive lymphocytes play a role in the course of idiopathic dilated cardiomyopathy (IDC) and ischemic cardiomyopathy (ICM). Based on these observations, we hypothesized that anti-p53 antibody response may also occur in patients with heart failure due to ICM and IDC.

Aim: The aim of this study was to evaluate anti-p53 antibodies in the serum of patients with heart failure due to IDC and ICM.

Methods: 70 eligible patients with heart failure and severe left ventricular systolic dysfunction (mean fractional shortening 12.03±3.93%) were included in the study. The aetiology of heart failure was IDC in 26 patients and ICM in 44 patients, according to the angiographic and echocardiographic findings.

Results: Anti-p53 antibodies were not detected in any of the patients.

Conclusion: Anti-p53 antibodies do not occur in patients with heart failure due to IDC and ICM, possible explanations are discussed in the text.

Key Words: p53 • Anti-p53 • Heart failure • Autoimmunity • Autoantibodies

Received May 23, 2004; Revised September 21, 2004; Accepted January 27, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.